Ⅰ原著
英文原著
Kitami Y, Fukuoka T, Okura T, Takata Y, Maguchi M, Igase M, Kohara K, Hiwada K.
Molecular structure and function of rat platelet-derived growth factor beta-receptor gene promoter. J Hypertens. 16:437-445, 1998.

Kohara K, Uemura K, Takata Y, Okura T, Kitami Y, Hiwada K.
Postprandial hypotension: evaluation by ambulatory blood pressure monitoring.
Am J Hypertens. 11:1358-1363, 1998.

Kohara K, Jiang Y, Igase M, Takata Y, Fukuoka T, Okura T, Kitami Y, Hiwada K.
Postprandial hypotension is associated with asymptomatic cerebrovascular damage in essential hypertensive patients. Hypertension. 33: 565-568, 1999.

Takata Y, Kitami Y, Fukuoka T, Okura T, Hiwada K.
Novel cis element for tissue-specific transcription of rat platelet-derived growth factor beta-receptor gene. Hypertension. 33:298-302, 1999.

Kohara K, Zhao B, Jiang Y, Takata Y, Fukuoka T, Igase M, Miki T, Hiwada K.
Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol. 83: 367-370, 1999.

Kohara K, Igase M, Takata Y, Fukuoka T, Okura T, Kitami Y, Hiwada K.
Contribution of reflection of pressure wave on central systolic blood pressure in older hypertensive patients. J Am Geriatr Soc. 47: 499, 1999.

Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K.
Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol. 407:227-235, 2000.

Igase M, Okura T, Nakamura M, Takata Y, Kitami Y, Hiwada K.
Role of GADD153 (growth arrest- and DNA damage-inducible gene 153) in vascular smooth muscle cell apoptosis. Clin Sci. 100:275-281, 2001.

Takata Y, Kitami Y, Okura T, Hiwada K.
Peroxisome proliferator-activated receptor- activation inhibits interleukin-1-mediated platelet-derived growth factor- receptor gene expression via CCAAT/enhancer-binding protein- in vascular smooth muscle cells. J Biol Chem. 276:12893-12897, 2001.

Yang Z-H, Kitami Y, Takata Y, Okura T, Hiwada K.
Targeted Overexpression of CCAAT/enhancer-binding protein- Evokes Enhanced Gene Transcription of Platelet-Derived Growth Factor- Receptor in Vascular Smooth Muscle Cells. Circ Res. 89: 503-508, 2001.

Tang JR, Nakamura M, Okura T, Takata Y, Watanabe S, Yang ZH, Liu J, Kitami Y, Hiwada K.
Mechanism of oxidative stress-induced GADD153 gene expression in vascular smooth muscle cells. Biochem Biophys Res Commun. 290:1255-1259, 2002.

Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang ZH, Kohara K, Kitami Y, Hiwada K.
Soluble Fas ligand and atherosclerosis in hypertensive patients.
J Hypertens. 20:895-898, 2002.

Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K.
Vascular inflammation is negatively autoregulated by interaction　between CCAAT/enhancer-binding protein and peroxisome proliferator-activated receptor .
Circ Res. 91:427-433, 2002.

Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, Okura T, Higaki J, Graf K, Fleck E, Hsueh WA, Law RE.
C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation. 110:579-587, 2004.

Blaschke F, Leppaenen O, Takata Y, Caglayan E, Joey Liu, Fishbein MC, Kappert K, Nakamura KI, Fleck E, Hsueh WA, Law RE, Bruemmer D.
Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res. 95:e110-123, 2004.

Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, Hines OJ.
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res. 65:982-990, 2005.

Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, Bruemmer D.
Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways.
Circ Res. 96:e59-67, 2005.

Takata Y, Wang W, Chu V, Collins AR, Blaschke F, Bruemmer D, Caglayan E,
Lyon CJ, Tangirala RK, Higaki J, Law RE, Hsueh WA.
Transcriptional Repression of ATP-binding Cassette Transporter A1 Gene in　macrophage: A Novel Atherosclerotic Effect of Angiotensin II. Circ Res. 97:e88-96, 2005.

Blaschke F, Takata Y, Caglayan E, Collins A, Tontonoz P, Hsueh WA, Tangirala RK.
A Nuclear Receptor Corepressor-Dependent Pathway Mediates Suppression of Cytokine-Induced C-Reactive Protein Gene Expression by Liver X Receptor.
Circ Res.99:e88-99, 2006.

Huang D, Khoe M, Befekadu M, Chung S, Takata Y, Ilic D, Bryer-Ash M.
Focal Adhesion Kinase Mediates Cell Survival Via NF-{kappa}B and ERK Signaling Pathways. Am J Physiol Cell Physiol. 292:C1339-1352, 2007.

Osawa H, Ochi M, Kato K, Yamauchi J, Nishida W, Takata Y, Kawamura R, Onuma H, Takasuka T, Shimizu I, Fujii Y, Ohashi J, Makino H.
Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochem Biophys Res Commun. 355:342-346, 2007.

Osawa H, Ochi M, Tabara Y, Kato K, Yamauchi J, Takata Y, Nishida W, Onuma H, Shimizu I, Fujii Y, Miki T, Ohashi J, Makino H.
Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol. 69:74-80, 2008.

Yamauchi J, Osawa H, Takasuka T, Ochi M, Murakami A, Nishida W, Onuma H, Takata Y, Tabara Y, Miki T, Ohashi J, Makino H.
Serum resistin is reduced by glucose and meal loading in healthy human subjects. Metabolism. 57:149-156, 2008.

Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J, Makino H.
Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension. 51:534-539, 2008.

Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK.
PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A. 105:4277-4282, 2008.

A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
Makino H, Shimizu I, Murao S, Kondo S, Tabara Y, Fujiyama M, Fujii Y, Takada Y, Nakai K, Izumi K, Ohashi J, Kawamura R, Yamauchi J, Takata Y, Nishida W, Hashiramoto M, Onuma H, Osawa H.
Endocr J. 56: 1049-58, 2009.

Relationship between smaller calcifications and lipid-rich plaques on integrated backscatter-intravascular ultrasound.
Inaba S, Okayama H, Funada J, Hashida H, Hiasa G, Sumimoto T, Takata Y, Nishimura K, Inoue K, Ogimoto A, Ohtsuka T, Higaki J.
Int J Cardiol. 145: 347-8, 2010.

Dysfunctional central hemodynamic regulation after daily meal intake in metabolic syndrome.
Funada J, Takata Y, Hashida H, Matsumoto Y, Sato S, Hiasa G, Inoue K, Higaki J, Okayama H.
Atherosclerosis. 210, 268-73, 2010.

A at single nucleotide polymorphism-358 is required for G at -420 to confer the highest plasma resistin in the general Japanese population.
Onuma H, Tabara Y, Kawamura R, Tanaka T, Ohashi J, Nishida W, Takata Y, Ochi M, Yamada K, Kawamoto R, Kohara K, Miki T, Makino H, Osawa H.
PLoS One. 5: e9718, 2010.

Influence of meal intake on pulse wave indices in type 2 diabetes.
Morioka N, Funada J, Takata Y, Hashida H, Iwata T, Higaki J, Okayama H.
Hypertens Res. 33: 743-7, 2010.

The GCKR rs780094 polymorphism is associated with susceptibility of type 2 diabetes, reduced fasting plasma glucose levels, increased triglycerides levels and lower HOMA-IR in Japanese population.
Onuma H, Tabara Y, Kawamoto R, Shimizu I, Kawamura R, Takata Y, Nishida W, Ohashi J, Miki T, Kohara K, Makino H, Osawa H.
J Hum Genet. 55: 600-4, 2010.

Relatively lower central aortic pressure in patients with impaired insulin sensitivity and resistance: the Toon Health Study.
Tabara Y, Saito I, Nishida W, Kohara K, Sakurai S, Kawamura R, Onuma H, Takata Y, Osawa H, Miki T, Tanigawa T.
J Hypertens. 29: 1948-54, 2011.

Impact of type 2 diabetes on serial changes in tissue characteristics of coronary plaques: an integrated backscatter intravascular ultrasound analysis.
Inaba S, Okayama H, Funada J, Higashi H, Saito M, Yoshii T, Hiasa G, Sumimoto T, Takata Y, Nishimura K, Inoue K, Ogimoto A, Higaki J.
Eur Heart J Cardiovasc Imaging. 13: 717-23, 2012.

Association of hematological parameters with insulin resistance, insulin sensitivity, and asymptomatic cerebrovascular damage: the J-SHIP and Toon Health Study.
Tabara Y, Igase M, Saito I, Nishida W, Kohara K, Sakurai S, Kawamura R, Okada Y, Hitsumoto S, Onuma H, Nagai T, Takata Y, Uetani E, Takita R, Kido T, Ochi N, Osawa H, Tanigawa T, Miki T.
Clin Hemorheol Microcirc. 55: 297-311, 2013.

Plasma resistin is associated with single nucleotide polymorphisms of a possible resistin receptor, the decorin gene, in the general Japanese population.
Onuma H, Tabara Y, Kawamura R, Ohashi J, Nishida W, Takata Y, Ochi M, Nishimiya T, Kawamoto R, Kohara K, Miki T, Osawa H.
Diabetes. 62: 649-52, 2013.

Heart Rate Variability, Insulin Resistance, and Insulin Sensitivity in Japanese Adults: The Toon Health Study.
Saito I, Hitsumoto S, Maruyama K, Nishida W, Eguchi E, Kato T, Kawamura R, Takata Y, Onuma H, Osawa H, Tanigawa T.
J Epidemiol. 25: 583-91, 2015.

Clinical implication of blood glucose monitoring in general dental offices: the Ehime Dental Diabetes Study.
Harase T, Nishida W, Hamakawa T, Hino S, Shigematsu K, Kobayashi S, Sako H, Ito S, Murakami H, Nishida K, Inoue H, Fujisawa M, Yoshizu H, Kawamura R, Takata Y, Onuma H, Shimizu K, Hamakawa H, Osawa H.
BMJ Open Diabetes Res Care. 3: e000151, 2015.

Impact of heart rate variability on C-reactive protein concentrations in Japanese adult nonsmokers: The Toon Health Study.
Saito I, Hitsumoto S, Maruyama K, Eguchi E, Kato T, Okamoto A, Kawamura R, Takata Y, Nishida W, Nishimiya T, Onuma H, Osawa H, Tanigawa T.
Atherosclerosis. 244: 79-85, 2016.

Endoplasmic reticulum stress induced by tunicamycin increases resistin messenger ribonucleic acid through the pancreatic endoplasmic reticulum eukaryotic initiation factor 2α kinase-activating transcription factor 4-CAAT/enhancer binding protein-α homologous protein pathway in THP-1 human monocytes.
Hamada J, Onuma H, Ochi F, Hirai H, Takemoto K, Miyoshi A, Matsushita M, Kadota Y, Ohashi J, Kawamura R, Takata Y, Nishida W, Hashida S, Ishii E, Osawa H.
J Diabetes Investig. 7:312-23, 2016.

A genome-wide association study of plasma resistin levels identified rs1423096 and rs10401670 as possible functional variants in the Japanese population.
Kawamura R, Tabara Y, Tsukada A, Igase M, Ohashi J, Yamada R, Takata Y, Kawamoto R, Saito I, Onuma H, Tanigawa T, Yamada K, Kato N, Ohyagi Y, Miki T, Kohara K, Osawa H.
Physiol Genomics. 2016 (in press).

Dual Effects of a RETN Single Nucleotide Polymorphism (SNP) at -420 on Plasma Resistin: Genotype and DNA Methylation.
Onuma H, Tabara Y, Kawamura R, Ohashi J, Nishida W, Takata Y, Ochi M, Nishimiya T, Ohyagi Y, Kawamoto R, Kohara K, Miki T, Osawa H.
J Clin Endocrinol Metab. 2016 (in press).

Caglayan E, Blaschke F, Takata Y, Hsueh WA.
Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways.
Curr Opin Pharmacol. 5: 135-142, 2005.

Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA.
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes. Arterioscler Thromb Vasc Biol. 26: 28-40, 2006.

高田康徳
食事がAIやSBP2値に及ぼす影響について 「Arteraal Stiffness 動脈壁の硬化と老化」、MEDICAL VIEW. 13: 70-71, 2008.

高田康徳、大澤春彦
糖尿病治療薬Up to Date
グルコシダーゼ阻害薬の特徴と使い方
月刊糖尿病. 7: 56-68, 2009.

高田康徳
糖尿病食事療法まるごとガイド
脂質異常症がある糖尿病患者さん　　糖尿病ケア２０１３春期増刊.151-157, 2013.

高田康徳
糖尿病食事療法まるごとガイド
高血圧がある糖尿病患者さん　　糖尿病ケア２０１３春期増刊.142-150, 2013.

高田康徳、大澤春彦
降圧薬の選択と使用法
糖尿病.57: 504-506,2014.

高田康徳、大澤春彦
糖尿病の個別治療と臨床検査
Schneller.9-21,2014.

高田康徳、大澤春彦
見えてきたSGLT2阻害薬の実力と新たな糖尿病治療薬の可能性
各種SGLT2阻害薬の特徴
Mebio.32, 3月号,2015.

高田康徳、大澤春彦
定期的なアルブミン尿・eGFRの評価が、透析導入や心血管病抑制の鍵となる
愛媛医学. 第３５巻第４号: 167-170, 2016.

高田康徳　主要な降圧薬の薬理作用と特徴：利尿薬
高血圧治療ガイドブック フジメデイカル出版 88-89, 1999.

高田康徳　合併症を伴った高血圧患者：痛風、高尿酸血症
高血圧治療ガイドブック フジメデイカル出版 164-165, 1999.

高田康徳　糖尿病を合併した高血圧の治療
１００症例から学ぶ高血圧治療UPDATE 日経メデイカル, 2000.

高田康徳　ペルオキソーム増殖剤応答性受容体 「KEY WORD:分子高血圧」
先端医学社, 156-157, 2002.

高田康徳、大澤春彦
糖尿病を合併する高血圧
降圧薬のエビデンス　医薬ジャーナル社107-117,2009.

高田康徳、大澤春彦
糖尿病診療に必要な臨床検査と指標
糖尿病治療のニューパラダイム　医薬ジャーナル社 93-103,2014.

高田康徳他
糖尿病診療ガイドライン2016.

１．高田康徳　海外ラボ紹介：Division of Endocrinology,Diabetes and　Hypertension,David Geffen School of Medicine,University of California,Los Angeles(UCLA)、
分子心血管病, 5(6) : 659-664, 2004.

２、高田康徳　海外通信：「UCLA医学部糖尿病，高血圧部門留学記」
CARDIAC PRACTICE、2005年7月号(Vol.16 No.3)